Investors in BioNTech SE are grappling with a pivotal moment for the Mainz-based biotech firm. The company faces a dual challenge: the impending departure of its visionary founders and a financial performance that has fallen short of market expectations. This confluence of events has triggered significant volatility in the company’s stock, raising urgent questions about who will guide its expensive strategic shift toward becoming a fully-fledged oncology company.
Financial Forecast Disappoints the Market
Recent financial disclosures have added to investor concerns. For the full year 2025, BioNTech reported an unadjusted net loss of €1.1 billion on revenues of €2.9 billion. More critically, the company’s forward guidance has underwhelmed analysts. Management projects 2026 revenues to be only between €2.0 billion and €2.3 billion, citing declining sales volumes for its COVID-19 vaccine in Europe and the United States. This forecast notably missed the average analyst estimate of €2.75 billion. Concurrently, research and development expenditures are expected to remain elevated, with a planned range of €2.2 billion to €2.5 billion.
The market’s reaction to this weak outlook was swift and severe. A substantial sell-off ensued, at one point driving the share price down by over 20% in a single trading session. Trading volume spiked to five times its usual average. The pressure pushed the stock to a new 52-week low of €72.50 on Tuesday before it found a slight foothold, closing at €78.35 on Wednesday.
Should investors sell immediately? Or is it worth buying BioNTech?
Founders Announce Departure to Pursue New Venture
Compounding the financial unease is a major leadership transition. The architect duo behind the company’s COVID-19 vaccine, Ugur Sahin and Özlem Türeci, plan to step down from their executive board roles by the end of 2026. Their intention is to establish a new, independent biotechnology company focused on cutting-edge early-stage mRNA research. In a related move, BioNTech is set to acquire a minority stake in this new entity in exchange for technology transfers and corresponding rights, with a binding agreement targeted for mid-2026. The supervisory board has already initiated a search for successors to ensure an orderly handover.
Oncology Strategy Remains the Core Focus
Despite the turbulence, BioNTech’s long-term strategic direction remains unchanged. The firm is committed to completing its transformation into a commercial multi-product company by 2030. Central to this plan is its late-stage oncology pipeline, which the company asserts will be unaffected by the management change. BioNTech aims to be running 15 parallel Phase 3 clinical trials by the end of 2026. A key priority is a bispecific immune modulator, developed in collaboration with Bristol Myers Squibb, which is slated to initiate eight global Phase 3 trials before the year is out.
Financing this costly late-stage research phase will be supported by a substantial war chest. The future management team will have access to €17.2 billion in liquid funds and investments. Organizational preparations for commercialization are already underway; Kylie Jimenez joined the executive board as Chief People Officer in early March to oversee global workforce expansion in anticipation of upcoming regulatory approvals and product launches.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from March 12 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 12.
BioNTech: Buy or sell? Read more here...
